NEW YORK, June 27, 2016 /PRNewswire/ -- This report analyzes the worldwide markets for Prostate Cancer Therapeutics in US$ Million by the following Segments: Hormone Therapy, and Other Therapies. The report provides separate comprehensive analytics for the US, Canada, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 76 companies including many key and niche players such as -
AbbVie, Inc.
Æterna Zentaris Inc.
Allergan plc
Amgen Inc.
Astellas Pharma Inc.
Read the full report: http://www.reportlinker.com/p03915682-summary/view-report.html
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Hormone Therapy.............. I-3 Other Therapies.............. I-4 Radiation Therapy.............. I-4 Immunotherapy.............. I-4 Chemotherapy.............. I-4
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW.............. II-1 Rising Incidence of Prostate Cancer: Cornerstone for the Market II-1 Table 1: Prostate Cancer Incidence Worldwide: Comparative Analysis for the years 2004, 2007, and 2012 (includes corresponding Graph/Chart)..............II-1 Current & Future Analysis..............II-2 Market Outlook & Trends..............II-2 Zytiga (Abiraterone acetate): The Market Leader II-2 Table 2: Global Prostate Cancer Therapeutics by Leading Drug (2015): Percentage Market Share Breakdown of Value Sales for Zytiga, Xtandi, Lupron, Zoladex, Taxotere, Jevtana, Xofigo & Others (includes corresponding Graph/Chart) II-3 Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC): 2016..............II-3 Hormone Therapies to Dominate Global Prostate Cancer Therapeutics Market..............II-5 Key Prostate Cancer Hormone Therapy Drugs & Companies: 2016 II-5 Targeted Therapy - The New Frontier of Cancer Treatment II-5 Radiotherapy - Gaining Prominence II-6 Metastatic Prostate Cancer - Apt for Precision Oncology II-6 Demographics & Lifestyles Raise the Risk of Prostate Cancer II-6 Table 3: Probability of Developing Invasive Prostate Cancer by Age Group in the US (includes corresponding Graph/Chart) II-7
Table 4: Male Population by Age Group in the US for the year 2014 (includes corresponding Graph/Chart) II-7 Select General Risk Factors and their Relative Risk Rate in Prostate Cancer.............. II-8 Small Cap Companies: A Target of Private Capital Financing II-8 Cost Analysis of Currently Available Treatment II-8 Table 5: Prices of Xtandi by Country (2016): Prices of Xtandi 40 mg Capsule/Tabs in the US and Other High-Income Countries (includes corresponding Graph/Chart) II-9 Growth Drivers.............. II-10 Rise in Prostate Cancer Incidence & Access to Modern Therapeutics Foster Growth..............II-10 Table 6: New Cancer Cases Diagnosed in the US by Site (2016): Percentage Share of Leading Cancer Sites (includes corresponding Graph/Chart)..............II-10 Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth.............. II-10 Table 7: Five-Year Prostate Cancer Survival Rate (%) Among US Males (2005-2011)..............II-11 Awareness Drives European Prostate Cancer Therapeutics Market II-11 Minimally Invasive Devices to Gain Share in Emerging Markets II-11 Supportive Cancer Drugs Contribute to Growth II-12 Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer..............II-12 Developments in Proteomics Favor Market II-12 Molecular Imaging of Cancer: Critical in Improving Patient Outcomes.............. II-13 Growth Restraints.............. II-14 Costly & Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance..............II-14 Limited Tumor Specificity and Toxicity II-14 Multiple Drug Resistance..............II-14 Stringent Regulations Delay Market Approval II-15 Challenges Faced by Patients and Clinicians in Diagnosis and Treatment.............. II-15 Challenges Encountered in Clinical Trials II-16 Select Recent Prostate Cancer Drug Trial Failures (As of 2016) II-16 High Development Costs Retracts Manufacturers in Developing Countries.............. II-16 Pipeline of Drugs in Clinical Trials II-17 New Products to Bolster Sales of Prostate Cancer Therapeutics II-17 Select Prostate Cancer Drugs in the Pipeline (2016) II-18 Marine Sponge-Derived Compound Shows Promise against Prostate Cancer.............. II-18 New Combination Treatment for Advanced mCRPC II-19 Risk of Alzheimer's dampens the Market II-19 Innovations & Advancements..............II-19 Research and Development Findings II-19 Additional Tests to be used with PSA for Better Diagnosis of Prostate Cancer.............. II-20 New Approaches in Diagnosis and Staging of Prostate Cancer II-21 New Developments in Treatment Methods and Diet Strategies II-22 Innovative mCRPC Treatment Options to Enhance Quality of Life II-23 New Drug Class (sphingolipid pathway inhibitor) Shows Potential for Slowing down Growth II-24 Neural Stem Cell Therapy: Revolutionary Step to Combat Cancer II-24 Combination of Therapies under Research II-26 Future Research Strategies to Benefit from Open Access Publishing.............. II-26 Innovations in Drug Delivery: A Key Factor in Product Differentiation.............. II-26
2. PRODUCT OVERVIEW.............. II-27 Cancer: A Major Health Crisis in the Modern World II-27 Prostate - Structure..............II-27 Pituitary Gland.............. II-27 Testes.............. II-28 Prostate Cancer - A Primer..............II-28 Key Facts.............. II-28 Table 8: Lifetime Probability of Developing Prostate Cancer by Age (%) - 2010-2012 (includes corresponding Graph/Chart) II-29
Table 9: New Incidence Rate of Prostate Cancer (Rate per Million Population) Worldwide for 2012 (includes corresponding Graph/Chart)..............II-30 Screening/Detection of Prostate Cancer II-30 Digital Rectal Exam (DRE)..............II-30 Transrectal Ultrasound (TRUS) II-30 PSA Blood Test.............. II-31 Strategies to Enhance Screening/Detection of Prostate Cancer II-31 Improved PSA Testing..............II-31 Total PSA, Free PSA and PSA-Alpha-1-Protease Inhibitor Levels II-31 Insulin-like Growth Factor (IGF-1) and Intact IGF-Binding Protien-3 (IGF-BP3)..............II-32 GSTP1 Methylation Levels and Prostate Cancer Diagnosis II-32 Microbubble Ultrasound..............II-32 Staging of Prostate Cancer..............II-33 Gleason Score.............. II-33 Gleason Score and Grading of Prostate Cancer II-33 TNM Staging.............. II-34 T-Staging Analysis of Prostate Cancer II-34 Genetic & Non-Genetic Factors..............II-35 Hereditary or Genetic Factors II-35 Non-Genetic or Environmental Factors II-35 Table 10: Prostate Cancer Incidence/Mortality Rate in the US by Ethnicity (2008-2012) (includes corresponding Graph/Chart).............. II-36 Prevention of Cancer..............II-37 Role of Diet in Prostate Cancer..............II-37 Treatment Options for Prostate Cancer II-38 Hormonal Therapy.............. II-39 Medical Hormone Therapy..............II-39 LHRH Analogs.............. II-39 Dose of LHRH Agonists for Advance Prostate Carcinoma Treatment II-40 Anti-Androgens.............. II-40 Anti-Androgen Monotherapy..............II-41 Orchiectomy.............. II-41 Side Effects of Orchiectomy..............II-42 Time to Start Hormonal Therapy..............II-42 Strategies to Enhance Hormonal Treatment II-42 Combination Therapy..............II-42 Intermittent Therapy..............II-42 Radiation Therapy.............. II-42 Brachytherapy.............. II-43 Treatment Procedure..............II-44 Benefits of Brachytherapy..............II-45 Drawbacks of Brachytherapy..............II-45 High Dose Rate (HDR) Brachytherapy II-45 External Beam Radiation Therapy (EBRT) II-46 Side Effects of Radiotherapy..............II-46 Strategies to Enhance Radiation Treatment II-46 Chemotherapy.............. II-47 Risks Associated with Chemotherapy II-48 Surgical Procedures for Prostate Cancer II-48 Transurethral Resection of the Prostate (TURP) II-48 Prostatectomy and Lymph Node Dissection II-48 Radical Prostatectomy..............II-49 Cryosurgery.............. II-49 Advantages of Cryosurgery:..............II-50 Disadvantages of Cryosurgery:..............II-50 Other Treatment Options..............II-50 Intensity Modulated Radiation Therapy (IMRT) II-50 Benefits of IMRT..............II-51 Drawbacks of IMRT.............. II-51 Androgen Deprivation Therapy (ADT) II-51 High Dose Radiation (HDR) Monotherapy II-52 Drawbacks of HRD..............II-52 Choosing the Optimal Treatment Method II-52 Recurrent Prostate Cancer..............II-53 Recurrent Prostate Cancer Subsequent to Surgery II-53 Recurrent Prostate Cancer Subsequent to Radiation Therapy II-53 Hormone-Refractory Prostate Cancer (HRPC) II-54 Select Drugs for Hormone-Refractory Prostate Cancer II-54 Chemotherapy.............. II-54 Taxotere® (Docetaxel)..............II-54 Bone Complication Treatments..............II-55 Bisphosphonate Drugs..............II-55 Radiation Therapy.............. II-55 Strategies to Enhance Recurrent Prostate Cancer Treatment II-56 Chemotherapy - New Regimens..............II-56 Phase I Clinical Trials..............II-56 Combination Therapy.............. II-56 Gene Therapy.............. II-56 Targeted Therapy.............. II-57 Selective Endothelia A Receptor Antagonist - (SERA™) II-57 Other Select Targeted Therapies II-58 Tyrosine Kinase Inhibitors..............II-58 Anti-Angiogenic Drugs..............II-58 Monoclonal Antibodies..............II-58 Vaccines.............. II-58 Radioactive Monoclonal Antibodies II-58
3. DRUG APPROVALS AND CLINICAL STUDIES II-59 EMA Issues Positive Opinion to Include Data in European Label for XTANDI.............. II-59 Cofepris Approves Weizmann Institute Drug TOOKAD® Soluble II-59 OncBioMune Pharmaceuticals Reports Positive Phase 1 Results of ProscaVax.............. II-59 FDA Accepts Xtandi sNDA by Astellas Pharma for Review II-59 Progenics Pharmaceuticals Begins Phase 3 Clinical Trial Enrollment for 1404..............II-59 FDA Grants Astrazeneca's Lynparza™ Breakthrough Therapy Designation.............. II-59 Nanobiotix's Investigational New Drug NBTXR3 Set for First Clinical Trial.............. II-60 Minomic International to Launch Human Trial of Its MAb Technology II-60 Takeda Receives NDA Approval for Leuplin II-60 Progenics Enters into Licensing Agreement with Johns Hopkins for Clinical-Stage PSMA Agent II-60 ZYTIGA Receives FDA Approval for Label Update II-60 Valeant Reports Long-Term results of Phase II STAND Trial of PROVENGE.............. II-60 OncoGeneX Pharmaceuticals to Regain Rights on Experimental Drug Custirsen from Teva..............II-61 Aeterna Announces Publication of Phase 1 Data for zoptarelin doxorubicin.............. II-61 EC Grants Variation to Marketing Authorization for Astellas' XTANDI.............. II-61 USFDA Approves New Indication for XTANDI II-61 Advaxis Enters Into Clinical Trial Collaboration with Merck II-61 Takeda Terminates Clinical Development of Orteronel II-61 Arno Therapeutics Enrols First Patient into Phase I/II Trial for Onapristone.............. II-61
4. PRODUCT LAUNCHES.............. II-62 GenomeDx Biosciences Launches Decipher Biopsy Test for Prostate Cancer.............. II-62 Profound Medical and Siemens Sign Agreement to Launch TULSA- PROTM System.............. II-62 Aeterna Zentaris Begins Promotional Activities for APIFINY® Test II-62 Biocept Launches Androgen Receptor Expression Assay for Prostate Cancer Detection..............II-62 Augmenix Reports Robust Commercial Uptake of SpaceOAR® System during Radiotherapy..............II-62 MDxHealth SA Launches SelectMDx Test in Europe II-62 Bayer Launches Xofigo in Ontario II-63 Debiopharm Group & Actavis Launch Trelstar with New, Convenient 6-Month Dosing..............II-63 Analogic to Launch D&K Technologies' BioJet™ Solution II-63 OPKO Health Launches 4Kscore™ Test II-63
5. RECENT INDUSTRY ACTIVITY..............II-64 UCLA Sells Xtandi Rights to Royalty Pharma II-64 Aytu BioScience Enters into Study Agreement with Hybridyne Imaging Technologies..............II-64 Crown Bioscience Signs Licensing Agreement with University of York for PDX Models..............II-64 Hologic Acquires DiagnoCure's Prostate Cancer Biomarker Assets II-64 Aeterna Zentaris Enters into Co-Marketing Agreement with Armune II-64 Exiqon Acquires Licensing Rights on Prostate Cancer Biomarkers from University Hospital..............II-64 Mylan Sued for ANDA for Generic Version of Zytiga II-65 Aytu BioScience Acquires Jazz Pharmaceuticals' rights to ProstaScint.............. II-65 OPKO Health to Acquire Bio-Reference Laboratories II-65 Boston Scientific to Acquire American Medical Systems' Urology Portfolio.............. II-65 Valeant to Acquire Dendreon's Assets II-65 Inovio Terminates Collaboration Agreement with Roche to Independently Develop Prostate Cancer Therapy II-65 GenomeDx Biosciences Expands Agreement with Mayo Clinic for Decipher® Prostate Cancer Classifier II-66 Catalent Collaborates with Minomic to Develop ADC for Prostate Cancer.............. II-66 Orion Enters Into Global Partnership with Bayer for Development of ODM-201..............II-66 Aduro BioTech Grants License to Janssen for Prostate Cancer Therapeutics.............. II-66 MDxHealth SA Signs Agreement with Prime Health Services II-66
6. FOCUS ON SELECT GLOBAL PLAYERS..............II-67 AbbVie, Inc. (US).............. II-67 Æterna Zentaris Inc. (Canada)..............II-67 Allergan plc (Ireland)..............II-67 Amgen Inc. (US).............. II-68 Astellas Pharma Inc. (Japan)..............II-68 AstraZeneca Plc. (UK)..............II-69 Bavarian Nordic (Denmark)..............II-69 Bayer Healthcare AG (Germany)..............II-70 Bristol-Myers Squibb Company (US) II-70 Debiopharm Group (Switzerland) II-70 Endo Pharmaceuticals Inc. (US) II-71 F. Hoffmann-La Roche Ltd. (Switzerland) II-71 Genentech Inc. (US)..............II-72 GlaxoSmithKline Plc. (UK)..............II-72 Janssen Biotech, Inc. (US)..............II-73 Novartis AG (Switzerland)..............II-73 Pfizer Inc. (US).............. II-74 Progenics Pharmaceuticals, Inc. (US) II-74 Sanofi S.A. (France)..............II-74 Spectrum Pharmaceuticals, Inc. (US) II-75 Takeda Pharmaceutical Company Limited (Japan) II-75 TOLMAR Pharmaceuticals, Inc. (US) II-76 Valeant Pharmaceuticals International, Inc. (Canada) II-76
7. GLOBAL MARKET PERSPECTIVE..............II-77 Table 11: World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-77
Table 12: World Historic Review for Prostate Cancer Therapeutics by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-78
Table 13: World 14-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............II-79 Segmental Analytics.............. II-80 Table 14: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-80
Table 15: World Historic Review for Hormone Therapy by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-81
Table 16: World 14-Year Perspective for Hormone Therapy by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-82
Table 17: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-83
Table 18: World Historic Review for Other Therapies by Geographic Region/Country - US, Canada, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-84
Table 19: World 14-Year Perspective for Other Therapies by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Europe, and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-85
III. MARKET
1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 A Surging US Prostate Cancer Therapeutics Market III-1 Prostate Cancer Stats: Opportunity Indicator III-1 Table 20: Prostate Cancer Incidence and Mortality in the US by Select Leading States (2016): No. of New Cancer Cases and No. of Deaths from Prostate Cancer (includes corresponding Graph/Chart)..............III-1
Table 21: Prostate Cancer Incidence/Mortality Rate in the US by Ethnicity (2008-2012) (includes corresponding Graph/Chart).............. III-2
Table 22: Male Population by Age Group in the US for the year 2014 (includes corresponding Graph/Chart) III-2
Table 23: Probability of Developing Invasive Prostate Cancer by Age Group in the US (2010-2012) (includes corresponding Graph/Chart)..............III-3 Other Cancer Related Statistics III-3 Table 24: Mortality in the US for the Year 2014 by Ailment- No. of Deaths & Percentage Breakdown for Heart Diseases, Cancer, Cerebrovascular Diseases (CVD), Chronic Lower Respiratory Diseases, Accidents (Unintentional Injuries), Alzheimer's, Diabetes, and Others (includes corresponding Graph/Chart).............. III-3
Table 25: Cancer Deaths in the US (2016) by Site & Gender: No. of Deaths by Cancer Type - Lung & Bronchus, Prostate, Colon & Rectum, and Breast (includes corresponding Graph/Chart).............. III-4
Table 26: New Cancer Case Estimates in the US by Site (2016): Percentage Share of Leading Cancer Sites in Men (includes corresponding Graph/Chart) III-4
Table 27: Lifetime Probability of Development of & Death from Cancer (in Men) by Type in the US, 2010-2012 III-5 Hormone Therapy Dominates Prostate Cancer Drugs Market III-5 Table 28: The US Prostate Cancer Therapeutics by Leading Drug (2015) - Percentage Share of Value Sales for Zytiga, Xtandi, Jevtana, Xofigo, Provenge & Others (includes corresponding Graph/Chart)..............III-5 High Intensity Focused Ultrasound (HIFU) Approved for Ablation of Prostate Tissue III-6 Clinical Trials.............. III-6 Product Launches..............III-8 Strategic Corporate Developments III-9 Select Key Players..............III-11 B.Market Analytics..............III-16 Table 29: The US Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-16
Table 30: The US Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-17
Table 31: The US 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-18
2. CANADA.............. III-19 A.Market Analysis.............. III-19 Prostate Cancer Stats: Opportunity Indicators III-19 Table 32: New Cancer Cases in Canada by Site (2015): Percentage Breakdown of New Cancer Cases Diagnosed for Prostate, Colorectal, Lung, Bladder, Non-Hodgkin Lymphoma, and Others (includes corresponding Graph/Chart) III-19
Table 33: Prostate Cancer Incidence in Canada by Leading Province: 2015 (includes corresponding Graph/Chart) III-20
Table 34: Prostate Cancer Mortality in Canada by Leading Province: 2015 (includes corresponding Graph/Chart) III-20
Table 35: Prostate Cancer Incidence and Mortality in Canada by Age Group: 2015 (includes corresponding Graph/Chart) III-21 Clinical Trial.............. III-21 Product Launches..............III-21 Strategic Corporate Developments III-22 Select Key Players..............III-22 B.Market Analytics..............III-24 Table 36: Canadian Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-24
Table 37: Canadian Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-25
Table 38: Canadian 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-26
3. EUROPE.............. III-27 A.Market Analysis.............. III-27 Awareness Drives European Prostate Cancer Therapeutics Market III-27 HIFU Technology Gaining Momentum in Europe III-27 Table 39: Prostate Cancer Prevalence in European Union by Diagnoses and Mortality (2012): Breakdown by Region/Country for No. of New Cases Diagnosed & No. of Deaths (includes corresponding Graph/Chart)..............III-28 B.Market Analytics..............III-29 Table 40: European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region/Country - France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-29
Table 41: European Historic Review for Prostate Cancer Therapeutics by Geographic Region/Country - France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-30
Table 42: European 14-Year Perspective for Prostate Cancer Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, United Kingdom, Spain, and Rest of Europe Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-31
Table 43: European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-32
Table 44: European Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-33
Table 45: European 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-34
3a. FRANCE.............. III-35 A.Market Analysis.............. III-35 Sanofi S.A. - A Key France-based Player. III-35 B.Market Analytics..............III-36 Table 46: French Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-36
Table 47: French Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-37
Table 48: French 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-38
3b. GERMANY.............. III-39 A.Market Analysis.............. III-39 Strategic Corporate Development III-39 Select Key Player.............. III-39 B.Market Analytics..............III-40 Table 49: German Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-40
Table 50: German Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-41
Table 51: German 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-42
3c. ITALY.............. III-43 Market Analysis.............. III-43 Table 52: Italian Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-44
Table 53: Italian Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-45
Table 54: Italian 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-46
3d. THE UNITED KINGDOM..............III-47 A.Market Analysis.............. III-47 Table 55: Prostate Cancer Incidence in the UK by Region (2013): No. of New Cases Diagnosed in England, Wales, Scotland, and Northern Ireland (includes corresponding Graph/Chart).............. III-47 Prostate Cancer Research in UK - An Insight III-47 Need for Filling up Gaps in Provision of Care III-49 Dearth of Clinical Researchers III-49 Clinical Trial.............. III-50 Select Key Players..............III-50 B.Market Analytics..............III-52 Table 56: The UK Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-52
Table 57: The UK Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-53
Table 58: The UK 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-54
3e. SPAIN.............. III-55 Market Analysis.............. III-55 Table 59: Spanish Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-55
Table 60: Spanish Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-56
Table 61: Spanish 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) III-57
3f. REST OF EUROPE.............. III-58 A.Market Analysis.............. III-58 Product Launch.............. III-58 Strategic Corporate Development III-58 Select Key Players..............III-58 B.Market Analytics..............III-61 Table 62: Rest of European Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-61
Table 63: Rest of European Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-62
Table 64: Rest of European 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).............. III-63
4. REST OF WORLD.............. III-64 A.Market Analysis.............. III-64 Minimally Invasive Devices to Gain Share in Emerging Markets III-64 Cancer Market in Asia..............III-64 Australia.............. III-65 India.............. III-65 Table 65: New Incidence Rate of Prostate Cancer (Rate per Million Population) in Asia-Pacific and Latin America for 2012.............. III-65
Table 66: 5-Year Net Survival Rates (%) for Prostate Cancer among Adults 15 yrs of Age and Older (2005-2009) in Select Asian and Latin American Countries (includes corresponding Graph/Chart) III-66 Clinical Trials.............. III-66 Select Key Players..............III-67 B.Market Analytics..............III-68 Table 67: Rest of World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-68
Table 68: Rest of World Historic Review for Prostate Cancer Therapeutics by Type - Hormone Therapy and Other Therapies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-69
Table 69: Rest of World 14-Year Perspective for Prostate Cancer Therapeutics by Type - Percentage Breakdown of Dollar Sales for Hormone Therapy and Other Therapies Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).............. III-70
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 76 (including Divisions/Subsidiaries - 84)
The United States (47) Canada (6) Japan (4) Europe (23) - France (5) - Germany (3) - The United Kingdom (5) - Rest of Europe (10) Asia-Pacific (Excluding Japan) (4)
Read the full report: http://www.reportlinker.com/p03915682-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article